Drug Approval | December 10, 2021
China approves Brii Bio’s antibody combination to neutralise Covid-19
Brii Bio announces amubarvimab/romlusevimab combination received approval from NMPA
Brii Bio announces amubarvimab/romlusevimab combination received approval from NMPA
According to the companies’ preliminary data, a third dose provides a similar level of neutralizing antibodies to Omicron as is observed after two doses against wild-type and other variants that emerged before Omicron
The event was organized jointly by Oncology Forum and Fortis Cancer Institute, Delhi NCR
Lupin had earlier received the U.S. FDA acceptance of the Biologics License Application (BLA) for Its proposed biosimilar
MJ will be paid a one-time lumpsum licence fee of Rs 15 crore
This further adds to Biocon’s portfolio of vertically integrated complex drug products
Going forward, the fastest-growing regions in the generic pharmaceuticals market will be South America and the Middle East, where growth will be at CAGRs of 10.1% and 9.4% respectively
Applications supported by positive results from the pivotal Phase 3 POETYK-PSO clinical trial program demonstrating superior efficacy of deucravacitinib over Otezla (apremilast)
Researchers observed that the Pfizer/BioNTech and Moderna vaccines were 78% and 73% effective in preventing Covid-19 infections, respectively
The appraisal of the applications has been carried out based on the ranking methodology laid down in the operational guidelines of the Scheme
Subscribe To Our Newsletter & Stay Updated
